Brief: Resverlogix Announces Apabetalone Treatment Prior To Sars-Cov-2 (Covid-19) Exposure Significantly Reduces Viral Infection – Confirms Plans For Covid-19 Clinical Trial
22/12/2020 13:34
Dec 22 (Reuters) - Resverlogix Corp RVX.TO :
* RESVERLOGIX ANNOUNCES APABETALONE TREATMENT PRIOR TO
SARS-COV-2
(COVID-19) EXPOSURE SIGNIFICANTLY REDUCES VIRAL INFECTION –
CONFIRMS PLANS FOR COVID-19 CLINICAL TRIAL
Source text for Eikon: ID:nGNX6Xss8x
Further company coverage: RVX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Resverlogix
See all newsBrief: Resverlogix Confirms Focus On Treatment Of Post Covid-19 Conditions
Brief: Resverlogix Announces New Research Findings Highlighting Safety Of BD2-Selective BET Inhibitors
Brief: Resverlogix Announces Type C Meeting With FDA For Coral, A Phase 3 High-Risk Covid-19 Outpatient Study
Brief: Resverlogix Expands Phase 2B Clinical Trial For Covid-19 Treatment With First Site In Brazil And Second In Canada
Brief: Resverlogix Announces Commencement Of Patient Enrollment And Dosing In A Phase 2B Trial For COVID-19 Treatment